This paper describes a preclinical toxicology study designed to investigate the biological efficacy and safety profile of second-generation adenovirus for CFTR gene transfer into the baboon lung. This second-generation virus is deleted of El and contains a temperature-sensitive mutation in the E2a gene, which encodes a defective DNA-binding protein. Two distinct projects were undertaken. Group A animals received a first-generation adenovirus (Le., deleted of El) in an upper lobe at the time a second-generation virus was instilled into the contralateral upper lobe. The goal of study A was to compare the biology of each construct directly and to determine if an immune response to the first-generation virus affected the performance of the secondgeneration virus. Group B animals received a lacZ second-generation virus in an upper lobe at the same time the CFTR second-generation virus was instilled in the other upper lobe. Necropsies were performed 4 or 21 days after gene transfer and tissues were evaluated for recombinant gene expression and histopathology. Using a second-generation adenovirus, recombinant gene stability was prolonged and associated with a diminished level of perivascular infiammation as compared to first-generation vectors. Markedly diminished levels of hexon protein were present in tissues infected with second-generation as compared to first-generation virus. No evidence of viral shedding was evident. Furthermore, coadministration of first-and second-generation adenovirus did not affect the stability of transgene expression from the second-generation virus. These data suggest that second-generation adenoviral vectors provide an improved gene delivery vehicle, and thus may be useful in gene therapy for cystic fibrosis.
. Preclinical trials using first-generation adenoviral constructs to deliver the CFTR gene to cotton rats (Zabner et al., 1994) and nonhuman primates (Engelhardt et al., 1993a; Simon et al., 1993; Zabner et al., 1994) suggest that gene transfer is both feasible and safe. The potential efficacy of adenovirus gene delivery was shown by transferring human CFTR into nasal epithelia of CF mice and human bronchial CF xenografts; in each case, normalization of a Cl^ secretory response was achieved (Grubb ef a/., 1994; Goldman era/., 1995) . These stadies indicate that correction of the CF phenotype may be achieved using an adenovirus-mediated gene delivery system.
Toward this end, seven clinical trials evaluating the genetic reconstitation of CFTR expression in the human airway have been initiated (presentations at the 1994 North American Cystic Fibrosis Conference) and two early reports have been published recently (Zabner et al., 1993; Crystal et al., 1994) . Zabner et al., (1993) administered an El-deficient adenovirus encoding CFTR to the nasal airway epithelium of 3 CF patients. Nasal epithelial potential difference measurements suggested some correction after transgene delivery. However, the direct detection of gene transfer was problematic in that CFTR mRNA was not shown by conventional reverse transcription polymerase chain reaction (RT-PCR), but was detected after subsequent methodological alterations. Crystal et al. (1994) also reported the administration of a CFTR recombinant adenovirus to the nasal and bronchial epithelium of CF patients. Again, the efficiency of gene transfer into the human airway was low but detectable in nasal and bronchial epithelial samples from separate patients. Of note was the observation that the patient who received the highest intrapulmonary dose of adenovirus (2 X 10' pfu) developed a pulmonary inflltrate in the area of virus administration and had increased circulating levels of interleukin-6, resuhs suggesting an active inflammatory response. These investigations were useful in further defining limits surrounding the safety and efficacy of adenovirus-mediated gene therapy.
Both animal model studies and clinical trials have revealed that gene expression is transient and accompanied by the development of host cellular immune responses. An accumulating body of data suggests that animals develop an immunologic response to component(s) ofthe adenovirus, i.e., viral proteins and transgene product, that leads to generalized inflammation and destruction of the cells containing the recombinant gene (Yang er al., 1994a (Yang er al., , 1995 . This paradigm predicts that modifications in the recombinant virus that render it less able to express viral proteins would result in improved transgene stability and a diminished cellular inflammatory response. This led to the development of a second-generation recombinant adenovirus, which harbors an E2a temperature-sensitive mutation in an El-deleted recombinant virus (Horwitz 1978; Engelhardt et al., 1994b) . At nonpermissive temperatures, this second-generation adenovirus fails to express late gene products, presumably because the defective DNA-binding protein is incapable of contributing to the activation of the major late promoter (Engelhardt et al., 1994b) . In mice and cotton rats that received this virus, transgene stability was improved and the inflammatory response was both blunted and delayed (Engelhardt er al., 1994a,b; Yang et al., 1994b) .
The purpose of this study was to assess whether the benefits of second-generation adenovirus seen in the previous studies would be realized in preclinical trials using nonhuman primates. Furthermore, this stady provided an opportunity to assess whether coadministration of both first-and second-generation adenoviruses would affect second-generation virus transgene stability.
MATERIALS AND METHODS
Preparation and nomenclature of adenoviral vectors H5.110CBCFr/f and lacZ viruses are replication-deficient, El-deleted, sub360-based recombinant adenoviruses, harboring the TSl25 temperatare-sensitive mutation in the E2a region. The CFTR adenovirus contains the cDNA encoding human CFTR, while the lacZ adenovirus contains a cassette encoding the Escherichia coli ;S-galactosidase ()3-Gal). The H5.010CBa/p adenovirus was generated from the same recombinant adenoviral backbone, but retains the normal E2a region. This vector encodes the reporter gene, human placental alkaline phosphatase (ALP). Details conceming the construction of these adenoviral vectors and their nomenclatare has been previously described (Engelhardt et al, 1994a,b; Yang ef al, 1994b) .
General study design
Five male baboons, each weighing approximately 10 kg, were used in this stady. The baboons, species Papio papio, were juveniles caught in the wild. The animals were provided an acclimatization period of 2-3 weeks before any experiments were undertaken. Two distinct groups of experiments were performed, and the protocols are provided in Table 1 . A pilot study, designated group A, addressed the effect of administration of a first-generation ALP virus (HS.OlOCBalp) into the left upper lobe at the time a second-generation lacZ virus (H5.11 OCB/acZ) was instilled into the right upper lobe. This protocol allowed direct comparisons of both viruses within the same animal, as well as an assessment of the impact of immune responses to the first-generation virus on the biology of the second-generation virus. In addition, this study allowed the direct comparison of transgene stability and tissue histopathology in animals infected with first-and second-generation adenoviruses. The two different reporter genes, lacZ and ALP, were used to evaluate the persistence of gene expression. Virus administration was performed by bronchoscopy in the following manner. The baboons were without food or water ovemight. Atropine (0.04 mg/kg i.m.) was given to the animals to decrease airway secretions, followed by ketamine (10 mg/kg i.m.), which provided the initial anesthesia. Intravenous pentothal was administered as needed to provide an additional level of anesthesia during procedures. Intubation with a 5.0-mm cuffed endotracheal tabe was performed by direct laryngoscopy. Isoflurane at 2-3 liters/min was then used as an inhalational anesthetic. Oxygen at 1-2 liters/min was also administered via the endotracheal tabe. A Pentax 10-X bronchoscope was passed via the endotracheal tabe into the trachea and the pulmonary airways were briefly examined. In Group A, first-generation recombinant adenoviras was instilled into the apical-posterior Long term segment of the left upper lobe and second-generation adenoviras into the posterior segment of the right upper lobe. Each viras (2 X 10^0 pfu/ml) was delivered in a small volume (1 ml/10 kg of body weight) to minimize alveolar spread. Pulse oximetry was used throughout the procedure to monitor the heart rate and oxyhemoglobin sataration of the animals. After the procedure, the animals were placed in recovery cages and their vital signs monitored until they regained consciousness. Necropsies were performed 4 and 21 days after adenoviral gene administration and tissue samples were evaluated for viral DNA sequence, recombinant gene expression and persistence, and histopathology. The safety of adenoviral constracts was determined as the animals were evaluated for evidence of viremia, hematologic and chemistry profiles, chest radiographs, and overall clinical statas.
Based on preliminary results indicating improved transgene persistence and safety profile in second-versus first-generation recombinant adenovirases, further experiments were performed. These experiments, designated group B, formally examined the stability of transgene using the second-generation viras and the presence of any associated cellular inflammatory response. These properties were studied by administering second-generation virases into specific bronchopulmonary segments of animals. Second-generation CFTR viras was administered into the apical-posterior segment of the left upper lobe and second-generation lacZ viras into the posterior segment of the right upper lobe. The dose of viras and subsequent evaluations of the animals was the same as detailed for group A. One animal from group B was evaluated long-term with repeat bronchoscopies on day 4 and 21 to obtain cellular material by bronchoalveolar lavage and brashings. Cells obtained by these methods were sedimented onto slides, air-dried, and stained with a modified Wright's stain. The cell types were then identified and counted.
Specimen collection and chest radiographs
The animals were evaluated daily for assessment of abnormal behavior. Data collections consisting of seram chemistries, cell counts, viral cultures, urinalyses, arterial blood gases, and chest radiographs were obtained on each animal at the following timepoints: days -7, 0, 4, 8, 12, 15, 21, 30 , and 45. Day 0 represents the day of viras administration. Urine samples were collected by spontaneous voids or by suprapubic puncture. Analyses of venous blood samples and urine were performed by MedRoche laboratories. Arterial blood was drawn from the femoral artery into a syringe containing heparin and analyzed in the Blood Gas Laboratory at the Hospital of the University of Pennsylvania. Nasopharyngeal secretions and rectal stool samples were collected by cotton swabs. These samples, together with blood and urine, were assayed for adenoviras by antibody fluorescent unit (AFU) testing. Lastly, supine ventraldorsal and left lateral chest radiographs were obtained at each timepoint.
Antibody fluorescent unit assays
Biological samples were evaluated for the presence of wildtype or recombinant virases using the antibody fluorescent unit (AFU) assay. Briefly, 293 cells were seeded onto Nunc Permanox chamber slides. Nasopharyngeal, stool, and urine samples were sterilely filtered and aliquots applied to the growing cells in a seram-free media. Seram aliquots were also assayed. After 2 hr, media containing seram (final concentration 10% BS) was added and the incubation continued at 32°C for an additional 48 hr. Media was aspirated and immunocytochemistry to hexon protein was performed on the prepared slides. One plaque-forming unit of wild-type or recombinant viras (first-or second-generation viras) per slide was detected routinely in control samples.
Necropsy protocol
Euthanasia was performed by administering intravenous sodium pentobarbitol via the saphenous vein. Tissues were harvested in a predetermined order with the lungs removed last to minimize the possibility of cross-contamination with known viras-containing tissues. Dissection of the lungs from the animals was performed as previously described (Engelhardt ef al, 1993a; Simon er al, 1993) . Each lobe was sectioned into quadrants. The lingula was separated from the left upper lobe and treated as a distinct lobe. All tissue quadrants were further divided into samples for subsequent analyses such as: fresh frozen in OCT for in situ hybridization, immunocytochemistry, or his-tochemistry; fixed in formalin for histopathology; or snapfrozen in liquid nitrogen for nucleic acid analysis. Other tissues, including heart, hver, spleen, kidney, urinary bladder, brain, testes, and lymph nodes were harvested for nucleic acid analysis and histopathology.
Histochemical and immunohistochemical analysis of lungs for lacZ, ALP, and hexon gene expression Sections of fresh frozen tissue (6 jam) were used to perform either histochemistry or immunocytochemistry. lacZ expression was detected by staining in X-Gal solution for 4 hr. Immunohistochemical detection of the adenoviral proteins, hexon, and DNA-binding protein (DBP) were performed as described previously (Engelhardt ef al, 1993b) . Briefly, tissue sections were post-fixed in methanol for 10 min, air-dried, and blocked in 20% donkey seram for 30 min. AdS DNA-binding protein was detected by immunofluorescence using a specific hybridoma supematant. AdS hexon protein was detected with fluorescein isothiocyanate-labeled polyclonal antibody (AblOS6F, Chemicon).
Immunohistochemical detection of ALP was performed by using a mouse monoclonal antibody directed against human placental ALP (Elcaltech), followed by a secondary antibody, a donkey anti-mouse fluorescein isothiocyanate-labeled IgG (Jackson Laboratories).
In situ detection of CFTR and lacZ RNA Frozen sections (6 pm) were fixed in PBS containing 4% paraformaldehyde for 3-4 hr followed by dehydration through a graded series of ethanol. In situ hybridizations were performed as described previously (Engelhardt ef al, 1992) . Briefly, fixed sections were treated in 10 mg/ml proteinase K at 30°C for 30 min followed by acetylation in acetic anhydride and dehydration through a graded series of ethanol. Sections were then hybridized to ^^S-labeled RNA probes specific to CFTR or lacZ, generated using the Promega riboprobe system. The CFTR probe contains sequences specific to adenoviras-derived CFTR and as such will not hybridize to endogenous baboon CFTR transcripts. Sense and RNase pretreatment with antisense probes were used as controls for hybridization sensitivity. Sections were exposed to NBT-2 photoemulsion for 1 week and developed.
DNA preparation and PCR analyses
Total cellular DNA was isolated from tissues frozen in liquid nitrogen. Samples were minced, placed into digestion solution containing 10 mM Tris-Cl pH 8.0, 100 mM NaCl, 1 mM EDTA pH 8.0, 1% sodium dodecyl sulfate, and O.S mg/ml proteinase K, and incubated ovemight at 37°C. Phenol-chloroform extractions were perfonned and DNA precipitated using an equal volume of isopropanol.
Nested PCR primer sets were used to amplify viral hexon DNA. The first primer set was AdS S'-CAA TCC CTG AAG CGC CGA CGA TG-3' and S'-TAC CAC TGA GAT TCT CCT ATT TGA GG-3'. The nested primer set was AdS S' -GGT AAC GTG TCG TAT GTG TGT CAT G-3' and S'-TAT TTA CCT GTT TGA CCT TCG ACA CC-3' DNA samples were added to a PCR reaction master mix, overlaid with light mineral oil. and amplified 35 cycles (Perkin-Elmer DNA Thermocycler). An aliquot (4 pl) was removed and added to a second PCR reaction using the nested primers and again amplified through 35 cycles. A sample of the final amplification product was analyzed on a 1.2% agarose gel and visualized with ethidium bromide.
To amplify H5.1 lOCBCFT/f DNA, the primer set used were CFTR 5'-CCA GTG CTC ATT TGG ATC CAG-3' and SV40 5'-GGT TAC AAA TAA AGC AAT AGC ATC-3'. HS.llOCB/acZ DNA was amplified using the primer set sense 5'-GACGTCTCGTTGCTGCATA-3' and antisense S'-CAC-CGCACGATAGA-GATTC-3'. Aliquots were removed and the reaction products were analyzed on an agarose gel.
RESULTS

Study design
Group A: Initial experiments were performed with animals that were administered first-generation ALP viras and secondgeneration lacZ viras simultaneously in contralateral lungs to allow for direct comparison of these individual constracts in the same animal, as well as to evaluate the impact of immunological responses of the first-generation viras on the biology of the second-generation viras. This involved two animals: B18 was necropsied at day 4 and B20 was necropsied at day 21.
Group B: This was a more formal toxicology experiment in which the biological efficacy and safety of second-generation vimses were evaluated in 3 baboons necropsied on day 4 (B17) and day 21 (B19), or were kept for long-term studies (B21). Two different second-generation virases that express lacZ and CFTR were administered into contralateral lungs.
The results of Group A will initially be presented followed by a summary of the experience with Group B.
Group A-Recombinant gene expression in the firstversus second-generation virus Frozen tissue sections from animals were analyzed for lacZ and ALP expression. Figure I depicts these results for B18 and B20. LacZ-positive cells were detected by histochemistry staining with X-Gal whereas ALP-infected cells were localized with a monoclonal antibody directed against the human placental ALP protein. Immunocytochemistry was performed to detect recombinant-derived ALP to eliminate problems encountered with high endogenous alkaline phosphatase activity in histochemical analyses of the baboon lung. Right upper lung sections from B18, the animals necropsied 4 days after viras administration, revealed significant X-Gal staining-positive material, predominantiy alveolar in nature (Fig. IA) . Sections from the right upper lobe of B20, the animal necropsied at day 21, revealed diminished but detectable lacZ expression in the right upper lobe (Fig. IB) . This contrasts with our extensive experience with first-generation lacZ viras in baboon lung where we never detected expression at 21 days (Engelhardt ef al, 1993a) . There was no positive X-Gal staining in sections sampled from lobes other than the right upper lobe in any animal (data not shown). ALP expression was present at day 4 in the upper left lobe of B18 (Fig. IC) , however, none was seen at 21 days in B20 (Fig. ID) . Quantitative analysis of histo- chemical staining in these animals is presented in Table 2 . These stadies indicate that the second-generation viras is associated with prolonged transgene expression in vivo in baboons; expression, however, does diminish in the first 3 weeks. Results obtained with the lacZ second-generation viras in animals B18 and B20 were identical to that seen with the same viras in group B (animals B17 andB 19).
Group A-Adenovirus-evoked inflammatory changes Inflammatory changes were evaluated by chest radiography and subsequent histopathology at the time of necropsy. Supine ventral-dorsal and left lateral chest radiographs were taken of each animal throughout the stady. The following grading system was adopted to depict the location and severity of developing inflltrates (Simon ef al, 1993) . The upper, middle, and lower lung fields of each lung were separately graded for alveolar infiltrates: mild, minimally detectable infiltrate; moderate, inflltrate occupying one-fourth of the lung field; severe, infiltrate occupying one-half or more of the lung field. The location and severity of chest radiographic abnormalities in animals administered first-and second-generation viras in contralateral upper lobes are shown in Fig. 2 (summary) and Fig. 3 (representative radiographs) . Animals B18 and B20 developed moderate left upper lobe inflltrates by day 4 (site of first-generation viras administration). By day 8, the chest radiograph of B20 revealed the development of significant left upper lobe and lingular infiltrates with air bronchograms. The lingular inflltrate resolved by day 12, but a mild left upper lobe inflltrate persisted through day IS. In contrast, a mild inflltrate in the right upper lobe (site of second-generation viras administration) was first evident on day 8 and resolved by day IS. Of note, although B20 developed a marked radiographically apparent pneumonia, the animal always appeared healthy. No signs or symptoms of respiratory distress were ever present and the calculated alveolar to arterial oxygen gradient was not significantly different from the other animals.
The histopathologic results obtained from the necropsies corroborates the findings evident on the chest radiographs. Histologic evaluation was performed on multiple areas from each pulmonary lobe. The lingula was treated as a distinct lobe. The criteria used for grading the severity of inflammatory and pathologic changes were previously described (Engelhardt ef al, 1994a) . Lung tissues were scored primarily on the amount of perivascular inflammation present. The severity of the vascular inflammatory response directly correlated with the amount Second-generation lacZ viras was administered into the right upper lobe and first-generation ALP virus into the left upper lobe of animals that were necropsied 4 (B18) or 21 (B20) days later. Frozen tissue sections (6 pm) were mounted onto slides. Each pulmonary lobe was cut into quadrants from which four representative sections were analyzed for lacZ-or ALP-positive cells. /acZ-positive cells were detected by X-Gal histochemistry. ALP-positive cells were detected by immunofluorescence to human placental ALP. Sections from pulmonary segments other than the upper lobes did not show any lacZ-or ALP-infected cells. The data are scored in terms of the number of epithelial cells that stained positively (i.e., >1 10-1%, or not detected [ND] ). of interstitial inflammation. Further pathologic findings included the presence of peribronchial inflammation, an increase in bronchial-associated lymphoid tissue (BALT), extension of an inflammatory response into alveolar spaces, an increase in alveolar macrophages, and any presence of interstitial pneumonitis.
The location and severity of the pneumonitis in these necropsied animals is shown in Fig. 4 , group A. The left upper lung of B18 (site of first-generation viras instillation) had the most significant inflammatory response with representative sections revealing a marked perivascular inflammation, increased BALT, and the presence of an interstitial pneumonitis. The most significant areas of vascular inflammation were associated with a focal pneumonitis with reactive type II pneumocytes, an increase in intraalveolar macrophages and lymphocytes, and intraalveolar edema. Significant but markedly decreased pathology was found in the right upper lobe of this animal (site of second-generation viras instillation). The inflammatory response was largely resolved by day 21. Immunophenotyping revealed the inflammatory cells to be primarily CDS"*" (data not shown).
Group A-Immunocytochemical detection of late viral genes A comparison of viral gene expression between first-and second-generation adenoviras was performed using immunocytochemistry to detect hexon and DNA binding proteins. Figure 5 presents the analysis of lung tissue from B18, the animal necropsied 4 days after infusion of second-generation lacZ virus into the right upper lobe and first-generation ALP viras into the left upper lobe. Higher levels of immunocytochemical staining for hexon were seen in the left upper lobe (site of firstgeneration viras administration; Fig. SA ) as compared to the right upper lobe (site of second-generation viras administration; Fig. SB) . Tissue sections from the left lower lobe served as negative controls for antibody specificity and showed no immunoreactive staining (Fig. SC) . Thus, late adenoviral gene expression is diminished using a second-generation viras. Due to a high background, the level of DBP expressed was difficult to assess quantitatively (data not shown).
Group B-Toxicity and biological efficacy of secondgeneration adenovirus in baboon lung
The results from the group A experiments were encouraging, in that second-generation adenoviras-mediated gene transfer was more stable and provoked less of a host inflammatory response than did first-generation viras. Therefore, a formal evaluation of a second-generation CFTR adenoviras was undertaken in a preclinical toxicology stady in baboon lung (Table 1, group B). As before, the baboons were fully evaluated for clinical signs of viral infection. Nasopharyngeal, stool, seram, and urine samples were analyzed by antibody fluorescent unit assays for evidence of viremia. Complete blood counts and chemistry profiles, including seram electrolytes and transaminases, were performed to detect the development of any blood abnormalities. Bronchoalveolar lavage material was obtained to evaluate any change in the airway cellular profile after viras administration. Chest radiographs were performed to detect and follow the development of pulmonary inflltrates and, last, histopathologic abnormalities were determined by necropsy and microscopic evaluation of tissues.
Group B-General response of the animals
Physical examinations performed throughout the study revealed no fever, conjunctivitis, tachypnea, or tachycardia. The behavior of the animals remained normal during the experiment. The animals tolerated bronchoscopic instillation of the recombinant viras without complication, except that 2 animals (B17 and B21) vomited immediately after intratracheal intabation. No evidence of aspiration, however, was observed during their bronchoscopies. In the post-infection period, the animals continued to eat normally and their weight changed less than 2%.
Group B-Expression of transgenes
Transgene expression was analyzed by in situ hybridization with probes specific to recombinant-derived CFTR and lacZ. Frozen lung sections from the upper lobes of all animals were hybridized to ^^S-labeled sense probes and exposed to photoemulsion for 1 week. Positive signal was evident at the highest levels in tissues obtained 4 days after viras administration. Figure 6 shows hybridization of tissue from the right upper lobe to lacZ probe (Fig. 6A,B) and hybridization of tissue from the left upper lobe to the CFTR probe (Fig. 6C,D) . Diminished but detectable levels of transgene RNAs were present at 21 days (data not shown). As controls for specificity of the assay, serial sections were hybridized with sense probes (data not shown) or to an antisense probe of an RNase-pretreated section (Fig.  6E,F) . No signal was present in these sections. These results are consistent with the prolonged transgene expression evident in the animal administered second-generation viras in the group A experiment.
Group B-Distribution of adenoviral CFTR Adenoviral and transgene DNA sequences were localized to their site of instillation by PCR analyses. Viral DNA sequences were found only in the lung tissues specifically administered recombinant adenoviras and in hilar lymph nodes (Fig. 7) . Hexon DNA was present at day 21 in lung administered either first-or second-generation adenoviras. Spillover of viras to pulmonary tissues other than that of its initial administration appeared not to be problematic. No adenoviral hexon sequences were found in a variety of tissues evaluated, including testes, pancreas, stomach, liver, brain, and heart (data not shown). DNA samples from the upper lobes of all animals were also analyzed using primers specific to either lacZ or CFTR genes (Fig.  8) . CFTR DNA was localized to the left upper lobe of animals that received that recombinant viras. lacZ sequences were found in samples only from a right upper lobe origin. Again, these results indicate that cross-contamination of viras and spillover of viral material did not occur.
Group B-Clinical testing
Blood hemoglobin concentrations remained within the normal range in all animals during the weeks following incubation FIG. 3 . Series of chest radiographs from B20. First-generation viras HS.OlOCBalp was administered intrabronchially into the left upper lobe and second-generation viras HS.l lOCBlacZ into the right upper lobe. Chest radiographs were taken on day 0, before gene administration, and subsequentiy on days 4, 8, 12, IS, and 21. (data not shown). On day 15, B21 had a white blood cell count of 23.2, shghtiy elevated above the top normal range. Differential counts, however, were normal and the behavior of the animal appeared unchanged at this time. In all other animals and time points, white blood cell counts, white blood cell differential counts, and platelets were within the normal range (data not shown).
Seram electrolytes were normal and remained unchanged throughout the stady. Seram creatinine, blood urea nitrogen, calcium, phosphoms, total protein, and albumin were normal. Liver function tests [aspartate transaminase (AST), alanine transaminase (ALT), lactate dehydrogenase, alkaline phosphatase, and bilimbin] were normal except for mild but stable elevations of these values in B17 (data not shown). Marked elevations in semm lipase were present in all animals only on day 4, ranging from 120 U/liter to 440 U/liter. Aside from the elevation in lipase, no other evidence of pancreatitis was present, suggesting that the reported semm elevations may be spurious.
Arterial blood gases were also analyzed. Baseline pC02 was 40 ± 3.8 mmHg (mean ± SD, range 23-55 mmHg); slightiy elevated pC02 levels were likely due in part to a combination of hypoventilation and atelectasis, which has been reported when baboons are sedated (Guenter et al, 1969; Simon ef al, 1993) . Baseline p02 levels were 71 ± 12 mmHg (mean ± SD, range 53-97 mmHg). PO2 data were analyzed using the alveolar to arterial oxygen gradient [P(A -a)02] to compensate for changes resulting from presumed hypoventilation. The moderate elevations present in the A -a gradient, however, were probably contributed to by atelectasis and subsequent V/Q mismatch. Inspection of the relationship between [P(Aa)02] and the number of days post-infection does not reveal a marked difference between baboons within groups or between groups (data not shown). The lack of changes in oxygenation is somewhat unexpected in view of the dense infiltrates that developed in animals that received first-generation viras (Fig.  2, group A) . 6 . In situ localization of lacZ and CFTR RNA. BI7 received recombinant adenovimses HS.l lOCB/acZ into the right upper lobe and HS.l lOCBCFF/? into the left upper lobe. Frozen sections (6 pm) were analyzed by in situ hybridization using specific RNA probes for lacZ from tissue of the right upper lobe (A, bright field; B, dark field) or CFTR from tissue of the left upper lobe (C, bright field; D, dark field). Serial sections also were hybridized with a sense probe and the antisense probe after treatment of the section with RNase. Specific hybridization was never seen under these conditions, confirming the specificity of the assay. An example of a section from the left upper lobe hybridized with the CFTR antisense probe after RNase treatment is shown (E, bright field; F, dark field).
Group B-Inflammatory changes as a result of second-generation virus administration
To detect and follow pulmonary infiltrates, chest radiographs were performed. The grading system detailing the location and severity of inflltrates was described earlier in this paper. In the animals that received only second-generation recombinant adenoviras, mild infiltrates developed by day 8 and were gone by day 15 (Fig. 2, group B) . Left upper lobe inflltrates persisted slightiy longer than those in the right upper lobe. Thus, compared to fu-st-generation viras, radiographic infiltrates developed later, were markedly less severe, and resolved sooner.
Animals that received only second-generation viras demonstrated detectable pathology in both upper lobes (left greater than right) that was significantly less than what was found with first-generation viras (Fig. 4, group B) . The inflammatory responses were markedly diminished but still present at day 21. These data suggest that animals that received only temperataresensitive recombinant adenoviras experienced a markedly blunted but prolonged inflammatory response. Micronodules Group B-Bronchoalveolar lavage cell counts Bronchoalveolar lavage was performed on the long-term animal B21 at baseline before viras instillation and again on days 4 and 21. The apical-posterior segment of the left upper lobe was lavaged followed by the posterior segment of the right upper lobe. Approximately 50% of the instilled volume was recovered at each lavage. Baseline cell concentrations of bronchoalveolar lavage material were 1.8 X 10^ ± 1.1 X 10* cells/ml (mean ± SD). Cell numbers recovered during bronchoscopies showed no change relative to the day of infection or side on which the lavage was performed (data not shown). Examination of Wright-stained cells suggests a trend toward an increase in mononuclear cells by day 21 from both sides (Fig.  9) , a finding previously reported (Simon et al, 1993) . consisting of accumulations of macrophages were found scattered diffusely throughout the lung parenchyma in all animals. The macrophages in part contained a refractile dark greenishblack pigment, suggesting the presence of silicates. This finding was previously reported in wild-caught baboons (Simon et al, 1993) . Grossly and microscopically, the nonpulmonary organs contained no abnormalities referrable to gene treatment.
Group B-Recovery of adenovirus from recipient animals Each animal was evaluated for recovery of adenovirases by infecting replication-permissive 293 cells with biologic samples recovered from the animal and evaluating the cells with immunocytochemistry to hexon protein. Specimens from nasopharynx, stool, urine, and blood were obtained throughout the stady and analyzed for viras. All samples were negative (Table  3 ). In positive control samples, one plaque-forming unit per plate was detected consistently.
DISCUSSION
A comprehensive toxicology study in nonhuman primates was undertaken to address a variety of issues surrounding second-generation recombinant adenovirases. The major interests were in examining the persistence of transgene expression and determining the level of any accompanying inflammation.
In past experiments delivering frrst-generation adenoviras to nonhuman primates, transgene expression was dose related and transient (Engelhardt ef al, 1993a; Simon ef al, 1993) . At the highest dose of viras, inflammation was apparent by infiltrates on chest radiographs, conelating with the development of significant pneumonitis at necropsy (Simon ef al, 1993) . Our initial stadies were consistent with other toxicology experiments performed in nonhuman primates (Brody ef al, 1994; Zabner ef al, 1994) . Although the animals appeared clinically well, these results emphasized the need to search for gene delivery methods that would improve biological efficiency and reduce potential toxicities.
Linuted expression of transgene and an associated inflammatory response had been seen with adenoviras-mediated gene ttansfer to a host of tissues, with our experience focusing on lung (Engelhardt era/., 1993a (Engelhardt era/., , 1994a Simon ef a/., 1993; Yang et al, 1994b) , and liver (Engelhardt ef al, 1994b; Yang ef al, 1994a,c) . Stadies targeting El-deleted recombinant adenovirases to the liver of athymic, immune-deficient mice demonstrated improved ttansgene stabiUty (Yang ef al, 1994a) . Viewed collectively, these studies suggested that the immune system played a significant role in mediating tiie stability of recombinant gene expression. The studies by Engelhardt ef al (1994b) and Yang ef al (1994a) also revealed that first-generation adenovimses maintained some ability to express viral genes. More detailed immunologic studies in the mouse suggest that cytotoxic T lymphocytes directed to the transgene product and/or newly synthesized viral genes added to elimination of the genetically modified cells (Yang ef al, 1994b, 199S) . This insight laid the ground work for producing modified viral vectors (second-generation adenoviras) that have a reduced capacity to express viral genes and, thus, might decrease the development of any host inflammatory response. This hypothesis was borne out. In mice that were administered sec- (Yang ef al, 1994b) . One explanation is that the temperature-sensitive mutation is "leaky" at 37°C, only partiaUy ablating gene ttansfer. This situation would predict that more disabled vectors would perform even better. In addition, destractive cytotoxic T lymphocytes (CTLs) could be generated to the product ofthe transgene, making it impossible to ablate cellular immune responses totally through vector reconstraction when the ttansgene product is viewed as a neoantigen. In summary, safety and biological efficacy of gene delivery remain primary goals of CF gene tiierapy and, as such, second-generation adenovirases are a step toward those goals.
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